Study hypothesis – this study will assess the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: June 2014
Crohn's Disease (CD) is a life long disease that mainly affects young adults. There is evidence That gut tissue injury is the result of an abnormal immune response that involved multiple non immune cellular systems including the intestinal microvascular endothelial cell. Moreover, clinical studies have shown that 1-7% of irritable bowel disease (IBD) patients suffer from arterial and venous thromboembolic complication. Chronic inflammation has a major role in the development and propagation of endothelial dysfunction, which can lead to coronary artery disease. Endothelial dysfunction has been described in patients with various and diverse chronic inflammatory conditions. Over the last few years, dysfunction of vascular endothelium has been widely recognized as the first step in the development of atherosclerosis. Several inflammatory mediators, such as C-reactive protein (CRP), Tumor Necrosis Factor α, (TNF α), nitric oxide (NO), vascular endothelial growth factor, CD-40, interleukin-6 (IL-6), which are up-regulated in IBD, also are known to impact vascular impact. The normal endothelium produces a vasodilatatory response to ischemia referred to us as reactive hyperemia. Shear stress on the blood vessel wall leads to the production and release vasodilatation. With endothelial dysfunction there is often either a blunted vasodilatatory in response to ischemic event, and chronic inflammation. The hypothesis of this study is that patients with Crohn's disease have an increased incidence of endothelial dysfunction, which can be corrected or improved by treatment with anti TNF α. The purpose of our study was to assess endothelial function in patients with Crohn's Disease, before and after treatment (steroids, immunomodulators, and anti TNF α). This study assessed the presence of endothelial dysfunction in patients with Crohn's disease and evaluated the possible role of tumor necrosis factor (TNF)-α in the pathophysiology of this abnormality. In this study we will preformed an endothelial function test before and after treatment by Endopath device from Itamar medical, FDA approved. Safety- Each subject will be screened by clinical history, physical examination, electrocardiogram, chest X-ray, Mantoux test (PPD), routine chemical analysis, and biomarkers. The study protocol has been approved by the local institutional review board.
- Device: Endopath from Itamar medical – FDA approved device.
- endothelial function assessment by Endopath device
- Drug: Anti TNF Alfa.
- This study will assessed the presence of endothelial dysfunction in patients with Crohn’s disease before and after 12 weeks treatment of anti TNF α.
Arms, Groups and Cohorts
- endothelial dysfunction assessment
- This study is a one arm study . In this arm we will assess endothelial function (with Endopath device) in patients with Crohn’s disease, before and after treatment of anti TNF α and other medication, and evaluate the possible role of tumor necrosis factor (TNF)-α in the pathophysiology of this abnormality.
Clinical Trial Outcome Measures
- This study will assessed the presence of endothelial dysfunction in patients, C with crohn’s disease before and after 12 weeks treatment of anti TNF α. CDAI, CRP.
- Time Frame: 12 month
- In this study we will preformed an endothelial function test before and after 12 weeks of treatment, by Endopath device from Itamar medical, FDA approved. Endo-PAT tests can be carried out in both the office and hospital settings, with patients positioned either sitting or supine. Endo-PAT bio-sensors are placed on the index fingers of both arms. The test takes 15 minutes to complete, is very easy to perform, and is both operator and interpreter independent. Thermo-neutral, quiet surroundings are recommended. Endo-PAT quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff).
Participating in This Clinical Trial
- Non smoker – No history of IHD or other known risk factors for IHD Exclusion Criteria:
- Patients who had been treated with anti TNF α 4 weeks before the study – As well as those who received corticosteroids within 1 week before the study. – DM, IHD, CRF, SMOKER
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 40 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Carmel Medical Center
- Provider of Information About this Clinical Study
- Overall Official(s)
- Zittan Eran, Principal Investigator, CARMEL MEDICAL CENTER – HAIFA -ISRAEL
- Overall Contact(s)
- zittan Eran, M.D, 972-48250359, firstname.lastname@example.org
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.